← Back to patent-cliff list
MIB-626
Tier C — Watch / tradeMIB-626
Metro International Biotech LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Updating
Indications (approved)：Heart disease, Type 2 diabetes, Diabetic nephropathy, 急性肾损伤, COVID-19, Friedreich's ataxia, 唐氏综合征
Regional status
US
Phase II
2021-05-17
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MIB-626?
Approved indications include: Heart disease, Type 2 diabetes, Diabetic nephropathy, 急性肾损伤, COVID-19, Friedreich's ataxia, 唐氏综合征.
When does the MIB-626 patent expire?
No public expiry year is available for MIB-626 yet; this page updates once verified.
How do I get a quote for MIB-626 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21